Skip to main content
Abstract 26: RUNX1 as a transcriptional target of activated Shp2 (PTPN11) in juvenile myelomonocytic leukemia.
Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.
Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
Early morbidity and mortality in childhood acute lymphoblastic leukemia with very high white blood cell count.
Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols.
The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial.
The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.